RxDoctor Payments Data

Anna Vedina, MD

Internal Medicine · North Chesterfield, VANPI 1801093281

Payments from drug & device makers

$1,618in general payments, 2019–2025

Across 106 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$320
  • Novo Nordisk$310
  • Lilly USA, LLC$272
  • AbbVie$127
  • Pfizer$117
  • GSK$112
  • plus $361 from 12 others

What the payments were for

  • Food & beverage$1,59699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,618 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$111,735
Medicare patients
402
Services billed
2,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$70,576
EliquisApixaban72$64,259
JanuviaSitagliptin Phosphate70$59,978
OzempicSemaglutide35$45,094
JardianceEmpagliflozin28$39,247
XareltoRivaroxaban34$37,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$24,296
FarxigaDapagliflozin Propanediol27$20,493
TrulicityDulaglutide11$18,489
Xtampza ErOxycodone Myristate11$12,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$8,913
Wixela InhubFluticasone Propion/Salmeterol30$4,621
Rosuvastatin Calcium345$4,455
Atorvastatin Calcium568$4,052
Venlafaxine Hcl ErVenlafaxine Hcl28$3,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$272$89,06570 claims
PfizerEliquis, Paxlovid$117$65,68893 claims
Novo NordiskOzempic$310$45,09435 claims
Boehringer IngelheimJardiance$50$39,24728 claims
GSKTrelegy Ellipta$112$24,29624 claims
AstraZenecaFarxiga$320$20,49327 claims
AbbVieSynthroid$127$2,29155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →